2019
DOI: 10.1128/jcm.01637-18
|View full text |Cite
|
Sign up to set email alerts
|

Industry Perspectives on the WHO Essential Diagnostics List

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
3
1

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 3 publications
0
3
0
Order By: Relevance
“…The EDL has been favorably received by all key stakeholders, including industry. A recent survey of industry representatives showed that the diagnostics industry largely welcomes the WHO EDL initiative and agrees that it will help improve access to diagnostics in Low-and Middle-Income Countries (LMICs) [13]. Industry members, however, did express concerns about the use of EDL as a price capping tool, and the need for the document to be updated frequently to ensure uptake of new tools [13].…”
Section: Rationale For An Edlmentioning
confidence: 99%
“…The EDL has been favorably received by all key stakeholders, including industry. A recent survey of industry representatives showed that the diagnostics industry largely welcomes the WHO EDL initiative and agrees that it will help improve access to diagnostics in Low-and Middle-Income Countries (LMICs) [13]. Industry members, however, did express concerns about the use of EDL as a price capping tool, and the need for the document to be updated frequently to ensure uptake of new tools [13].…”
Section: Rationale For An Edlmentioning
confidence: 99%
“…It complements the WHO Essential Medicines List (EML) and links medicines with diagnostic tests to advance the UHC 11, 15 . It paves the way toward improved healthcare delivery and ultimately better patient outcomes by promoting greater equitable access to quality and affordable diagnostics at all levels of the healthcare delivery system 16 . To ensure its impact, countries will need to develop national lists that suit their national or regional needs, disease burdens, and health system capacities 2, 5, 17 .…”
Section: Introductionmentioning
confidence: 99%
“…It complements the WHO Essential Medicines List (EML) and links medicines with diagnostic tests to advance the UHC [11,15]. It paves the way toward improved healthcare delivery and ultimately better patient outcomes by promoting greater equitable access to quality and affordable diagnostics at all levels of the healthcare delivery system [16]. Countries need to adopt and develop national lists that suit their national or regional needs, disease burdens, and health system capacities to ensure their impact on healthcare practice and patient outcomes [2,5,17].…”
Section: Introductionmentioning
confidence: 99%